News summary

Lower-dose CagriSema cut body weight about 21% in phase 3b

Source: Longevity Docs News • Published: 16 Nov 2026, 00:00

Summarized by Masters of Longevity from Longevity Docs News.

Two lower weekly CagriSema doses cut weight by about 21% versus placebo.

Lower-dose CagriSema cut body weight about 21% in phase 3b
Key Takeaways
  • Two lower doses produced about 21% mean weight loss.
  • The trial excluded people with diabetes and was mostly women.
  • Doses were not compared head-to-head, so equivalence remains unproven.
Read the full article at Longevity Docs News ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.